SEC Filing Summary: Prestige Brands Holdings, Inc. (Form 8-K)
Business Context and Reporting Period
Date of Report: December 20, 2011
Company: Prestige Brands Holdings, Inc. (Delaware corporation)
Event: Entry into material definitive agreements to acquire over-the-counter (OTC) pharmaceutical brands from GlaxoSmithKline plc (GSK) and securing financing for the transactions.
Key Financial Metrics and Transaction Details
This filing details two acquisition agreements and a financing commitment rather than periodic financial performance metrics (revenue, profit, cash flow).
- Acquisition 1 (BSPA I): Purchase of 15 OTC brands (including BC, Goody's, Ecotrin, Beano, Gaviscon, Sominex) for $615 million in cash, subject to inventory adjustment.
- Acquisition 2 (BSPA II): Purchase of Debrox and Gly-Oxide brands for $45 million in cash, subject to inventory adjustment.
- Total Acquisition Consideration: $660 million (subject to adjustments).
- Financing Commitment: Aggregate principal amount of $960 million committed by Citibank, Morgan Stanley, and Royal Bank of Canada.
- Debt Structure:
- $620 million seven-year senior secured term loan.
- $50 million five-year senior secured revolving credit facility.
- $290 million one-year senior unsecured bridge facility (or senior unsecured notes).
Material Changes and Liabilities
The filing represents a material change in the company's capital structure and product portfolio pending closing.
- Termination Fees:
- BSPA I: $25 million payable to GSK if the Company fails to satisfy financing conditions and GSK elects to terminate.
- BSPA I Liability Cap: $40 million for material non-compliance or breach.
- BSPA II Liability Cap: $25 million for material non-compliance or breach.
- Indemnification: Provisions survive for 18 months post-closing, capped at 15% of the purchase price not allocable to inventory.
- Refinancing: Proceeds will be used to pay acquisition consideration and refinance the Company's existing credit facility.
Outlook, Risks, and Conditions
Closing Conditions:
- Clearance under the Hart-Scott Rodino Antitrust Improvements Act (HSR Act).
- Consummation of committed financing.
- Assignment and licensing of certain intellectual property rights (BSPA II).
- Absence of a Material Adverse Change.
Investor Verification Checklist
- Verify the status of HSR Act antitrust clearance for the $660 million acquisition.
- Confirm the final closing date and any post-closing inventory adjustments to the purchase price.
- Review the specific terms of the new $960 million credit facilities, including interest rates and covenants, in the full Commitment Letter (Exhibit 10.1).
- Assess the impact of the new debt load on the Company's leverage ratios and liquidity position.
- Monitor for any Material Adverse Change that could trigger termination of the agreements.